3-Aminopiperidine-2,6-Dione Hydrochloride CAS 24666-56-6;2686-86-4 Puritas >99.0% Lenalidomide Factory medium
Ruifu Chemical primarius est opificem 3-Aminopiperidini-2,6-Dionis Hydrochloridis (CAS: 24666-56-6; 2686-86-4) magna qualitate, media Pomalidomide (CAS: 19171-19-8).Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase 3-Aminopiperidine-2,6-Dione Hydrochloridis, Please contact: alvin@ruifuchem.com
| Nomen chemicum | 3-Aminopiperidine-2,6-Dione Hydrochloridis |
| Synonyma | 3-Aminopiperidine-2,6-Dione HCl;3-Amino-2,6-Piperidinedione Hydrochloridis;2,6-Dioxopiperidine-3-Ammonium Chloride |
| CAS Number | 24666-56-6 |
| Related CAS | 2686-86-4;25181-50-4 |
| Stock Status | In Stock, Productio Ascendite ad Tons |
| Formulae hypotheticae | C5H9ClN2O2 |
| M. Pondus | 164.59 |
| Liquescens punctum | 120℃ |
| COA & MSDS | Praesto |
| Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Off-White Crystalline pulveris |
| Puritas / Analysis Methodus | >99.0% (HPLC) |
| Humor (KF) | <0.50% |
| Damnum in Siccatio | <0.50% |
| Residere in Ignition | <0.20% |
| Totalis immunditias | <1.00% |
| Infrared Imaginis | Conformat ut Structure |
| Test Standard | Enterprise Standard |
| Consuetudinem | Medium Lenalidomide (CAS: 191732-72-6) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
3-Aminopiperidine-2,6-Dione Hydrochloridi (CAS: 24666-56-6; 2686-86-4) medium est ad Lenalidomidem praeparandum (CAS: 191732-72-6).Lenalidomide medicamenta quaedam est antitumoris quae a societatibus pharmaceuticis biologicis Americanis explicata est.Multa munera habet sicut anti-tumorem, ordinationem immunem et anti-angiogenesis.Secretionem cytokinorum inflammatoriae inhibere potest et excretionem sanguinis mononuclei anti-inflammatorii cytokinorum peripherici augere.Augmentum inhibere potest cellularum myelomarum multiplex et cellae MM1S aegrorum.Duo multicenter randomized duplices-caecus placebo moderato studiorum clinicorum aestimandi salutem et effectum curativum lenalidomidis, quod pro multiplici myeloma adhibetur.Recentes eventus investigationis clinicae ostendunt lenalidomidem non solum effectum curativum habere in curatione MDS et MM, sed etiam in tractando myeloma, leukemia, metastaticum cellam renum carcinoma, tuberculum solidum, amyloidosis idiopathicum generativum et systemicum ossis medullis fibrosi morbi cum medullis immaturis.Mense Decembri 2005, Cibus US et Administration medicamentis (FDA) probatus lenalidomide utendum est in tractatione syndrome myelodysplasticae (MDS).
